WJWiebke Jonas

Wiebke Jonas

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Wiebke Jonas has a total of 8 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Effects of 12 Weeks of Calanus Oil Supplementation on Cardiac Diastolic Function in Obese and Prediabetic Women—A Pilot Study

    by Felix Kerlikowsky, Fabian Spahiu, Eric J. Stöhr, Sina Junge, Wiebke Jonas, Edda van de Flierdt, Jan Philipp Schuchardt, Andreas Hahn

    Background/Objectives: In early-stage diabetes, diastolic dysfunction is an initial indicator of heart failure and is linked to altered glucose metabolism, including in prediabetes. Based on initial evidence that Calanus oil, derived from Calanus finmarchicus, which is rich in omega-3 polyunsaturated fatty acids and other bioactive compounds, benefits metabolic and cardiorespiratory health, this proof-of-principle study aimed to assess whether Calanus oil improves diastolic function in prediabetic women. Methods: Twenty middle-aged, obese women with prediabetes and no history of cardiac complications were enrolled and received 4 g/day of Calanus oil, providing 276 mg EPA + 256 mg DHA, for 12 weeks. Systolic and diastolic cardiac function, including the E/A ratio (E/A), was assessed by echocardiography. In addition, central blood pressure (BP) and pulse wave velocity (PWV) were analyzed by oscillometry. Metabolic health was evaluated using composite markers, including the metabolic syndrome severity score (Met-S score) and the triacylglycerol glucose–waist-to-height ratio (TyG-WHtR). Results: E/A was significantly improved (p = 0.023) following 12 weeks of Calanus oil supplementation. Furthermore, a significant improvement in metabolic health, indicated by a reduced Met-S score and a lower TyG-WHtR, was noticed (p < 0.001, respectively), reflecting decreased metabolic syndrome severity and enhanced insulin sensitivity. In addition, a significant reduction in diastolic BP, resting heart rate (p = 0.047), but not PWV or systolic BP (all p > 0.05) was observed. The improvement in E/A was associated with improved insulin sensitivity, as reflected by a decrease in the TyG-WHtR (p = 0.014). Conclusions: These exploratory findings suggest that Calanus oil supplementation in pre-diabetic women might improve central diastolic haemodynamics, accompanied by an overall improvement in metabolic health. However, the absence of a placebo control group limits definitive conclusions.


  • Open Access

    Effects of 12 Weeks of Calanus Oil Supplementation on Cardiac Diastolic Function in Obese and Prediabetic Women – A Pilot Study

    by Felix Kerlikowsky, Fabian Spahiu, Eric J. Stöhr, Sina Junge, Wiebke Jonas, Edda van de Flierdt, Jan Philipp Schuchardt, Andreas Hahn

    Background/Objectives: In early-stage diabetes, diastolic dysfunction is an initial indicator of heart failure and is linked to altered glucose metabolism, including in prediabetes. Based on initial evidence that Calanus oil, derived from Calanus finmarchicus which is rich in omega-3 polyunsaturated fatty acids and other bioactive compounds, benefits metabolic and cardiorespiratory health, this proof-of-principle study aimed to assess whether CALANUS OIL improves diastolic function in prediabetic women. Methods: Twenty middle-aged, obese women with prediabetes and no history of cardiac complications were enrolled and received 4 g/day of Calanus oil, providing 276 mg EPA+256 mg DHA, for 12 weeks. Systolic and diastolic cardiac function, including the E/A ratio (E/A), was assessed by echocardiography. In addition, central blood pressure (BP) and pulse wave velocity (PWV) were analysed by oscillometry. Metabolic health was evaluated using composite markers, including the metabolic syndrome severity score (Met-S score) and the triacylglycerol-glucose waist-to-height ratio (TyG-WHtR). Results: E/A was significantly improved (p=0.023) following 12 weeks of Calanus oil supplementation. Furthermore, a significant improvement in metabolic health indicated by a reduced Met-S score and a lower TyG-WHtR was noticed (p < 0.001, respectively), reflecting decreased metabolic syndrome severity and enhanced insulin sensitivity. In addition, a significant reduction in diastolic BP, resting heart rate (p=0.047) but not PWV or systolic BP (all p>0.05) were observed. The improvement in E/A was associated with improved insulin sensitivity, as reflected by a decrease in the TyG-WHtR (p=0.014). Conclusions: In prediabetic women, Calanus oil supplementation improved central diastolic haemodynamics, accompanied by an overall improvement of metabolic health.

  • Open Access

    Calanus Oil and Lifestyle Interventions Improve Glucose Homeostasis in Obese Subjects with Insulin Resistance

    by Felix Kerlikowsky, Madeline Bartsch, Wiebke Jonas, Andreas Hahn, Jan Philipp Schuchardt

    Obesity increases the risk for insulin resistance (IR) and type-2 diabetes. Lifestyle interventions (LI) and dietary supplementation can help mitigate IR. We investigated the effect of calanus oil (CO) supplementation, combined with LI, on glucose homeostasis in obese subjects. CO, a novel marine oil, contains omega-3 fatty acid wax esters as well as plant sterols and astaxanthin. In the double-blind, randomized, placebo-controlled 12-week intervention study, 266 subjects with distinct IR phenotypes were assigned to four groups: 2 g CO/day, 4 g CO/day, 2 g CO/day + LI, and placebo. The effect of CO on HOMA index reduction was influenced by the initial (t0) squared HOMA index (interaction p = 0.011). A post hoc test showed significant improvement with 2 g CO/day + LI (estimated marginal means [EMM] 95% confidence interval [CI]: −0.19 [−0.80–0.41], p = 0.021). Secondary analysis revealed that 4 g CO/day had significant effects in subjects with mild IR (HOMA index 2.5–5.0) (EMM [95% CI]: −0.76 [−1.53–0.03], p = 0.043). CO supplementation improved glucose homeostasis, with effects varying by dose, combination with LI, and IR phenotype.